Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Journal of Neuroscience
  • Log in
  • My Cart
Journal of Neuroscience

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE
PreviousNext
Research Articles, Neurobiology of Disease

VGLUT2 Is a Determinant of Dopamine Neuron Resilience in a Rotenone Model of Dopamine Neurodegeneration

Silas A. Buck, Briana R. De Miranda, Ryan W. Logan, Kenneth N. Fish, J. Timothy Greenamyre and Zachary Freyberg
Journal of Neuroscience 2 June 2021, 41 (22) 4937-4947; DOI: https://doi.org/10.1523/JNEUROSCI.2770-20.2021
Silas A. Buck
1Center for Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213
2Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Silas A. Buck
Briana R. De Miranda
3Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, 15260
4Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, 35294
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan W. Logan
5Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts, 02118
6Center for Systems Neurogenetics of Addiction, The Jackson Laboratory, Bar Harbor, Maine, 04609
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ryan W. Logan
Kenneth N. Fish
2Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Timothy Greenamyre
3Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, 15260
7Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, 15260
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zachary Freyberg
2Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213
8Department of Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zachary Freyberg
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Extended Data
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Rotenone-induced nigrostriatal degeneration causes motor deficits in adult rats. A, Representative images of Nissl-stained midbrain from rotenone- or vehicle-treated rats, indicating substantial neuronal cell body loss in the SNc in response to rotenone; 20× magnification. Dashed lines indicate SNc. Scale bar, 100 µm. B, Representative images of TH-immunostained DA neurons (red) from the SNc (left) and striatum (right) from vehicle- or rotenone-treated rats; 20× magnification. Dashed lines indicate SNc. Scale bars, 100 µm. C, Quantification of immunostained TH+ DA neurons in the SNc (Mann–Whitney U test, p = 0.0025) and (D) TH fluorescence intensity from TH+ nerve terminals in the dorsolateral striatum showed significant loss in response to rotenone compared with vehicle (Mann–Whitney U test, p = 0.0022). Striatal TH fluorescence intensity is normalized to vehicle condition. E, PIT of vehicle (black)- or rotenone (red)- treated rats shows impairment in rotenone-treated rats (H14 = 41.8, p < 0.001). Data are mean ± SEM. N = 5-7 per group for stereology and immunohistochemistry. N = 3 per group for PIT. *p < 0.05. **p < 0.01.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    VGLUT2-expressing DA neurons are more resistant to rotenone-induced cell loss. Representative images of TH and VGLUT2 mRNA in vehicle- and rotenone-treated rats. A, 4× and (B) 60× magnification images of VTA/SNc of vehicle-treated rats showed a high level of TH expression (red) and a subset of TH+ cells that coexpress VGLUT2 (green). Yellow arrows indicate TH+/VGLUT2+-coexpressing cells. Scale bars: 4× image, 2 mm; 60× image, 25 µm. Lipofuscin depicted in 60× images (white). C–I, Quantification of TH and VGLUT2 mRNA expression in rotenone- and vehicle-treated rats. C, D, Although TH mRNA grains per average cell volume were significantly decreased in rotenone-treated rats compared with vehicle (Mann–Whitney U test, p = 0.032; C), there was no change in VGLUT2 grains per average cell volume in rotenone-treated rats (Mann–Whitney U test, p = 0.99; D). E, There was a significant decrease in number of DAPI-stained nuclei in VTA and SNc in response to rotenone treatment. F, Rotenone diminished the number of TH+ cells in both VTA and SNc compared with controls. G, In contrast, TH+/VGLUT2+ cell numbers were not significantly changed with rotenone treatment. H, The percentage of TH+ cells that expressed VGLUT2 increased after rotenone treatment, indicating that TH/VGLUT2-coexpressing neurons were more resistant to rotenone-induced neurodegeneration. I, There was no increase in VGLUT2 expression within TH+/VGLUT2+ cells after rotenone. Data are mean ± SEM. N = 4 or 5 per group. *p < 0.05 compared with vehicle. #p < 0.05 compared with other regions.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Rotenone increases density of VGLUT2+ neurons. A, Rotenone treatment increased the total number of VGLUT2+ cells that did not also coexpress TH mRNA (TH–/VGLUT2+) (H1 = 4.6, p = 0.033). B, There was no change in VGLUT2 mRNA grain expression within TH–/VGLUT2+ cells in either VTA or SNc of rotenone-treated rats compared with the vehicle control. Data are mean ± SEM. N = 4 or 5 per group, *p < 0.05.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Rotenone upregulates VGLUT2 protein expression in surviving DA neurons. A, Representative 20× and (B) 100× images showing an upregulation of VGLUT2 in the VTA and SNc of rotenone-treated rats. Scale bar, 30 µm. C, While there was no significant change in relative intensity of VGLUT2+ puncta in either the VTA or SNc, there was a significant increase in (D) VGLUT2+ puncta density and (E) the number of VGLUT2-immunoreactive puncta within TH+ cells. Data are mean ± SEM. N = 3-8 per group. *p < 0.05. **p < 0.01.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Rotenone treatment alters actin cytoskeleton and VGLUT2 distribution in N27 cells. Representative images of the rat dopaminergic neuron N27 cell line showed increased VGLUT2 signal (green) in the cell body with accompanying retraction of cell processes and reorganization of cortical β-actin (red) after 100 nm rotenone treatment. Scale bar, 20 µm.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Rotenone leads to region-specific loss of TH protein and increased density of TH and VGLUT2-colocalizing puncta in the NAc. A, Representative 60× images showing loss of TH signal but no change in VGLUT2 in the CPu of rotenone-treated rats. Scale bar, 20 µm. B, There was a significantly lower TH signal intensity in the CPu (Dunn's post hoc p = 0.048), but not the NAc core (post hoc p > 0.99) or shell (post hoc p > 0.99), after rotenone treatment. Similarly, there was a significantly lower TH puncta density in the CPu (post hoc p = 0.048), but not in the NAc core (post hoc p > 0.99) or shell (post hoc p > 0.99), after rotenone treatment. C, There was no change in the intensity or density of VGLUT2+ puncta in nerve terminals within the CPu or NAc of rotenone-treated rats compared with vehicle (Kruskal–Wallis H test, all p > 0.06). D, Representative 60× images of TH (red) and VGLUT2 (green) puncta in the NAc core and shell in vehicle- and rotenone-treated rats. White circles represent colocalizing TH and VGLUT2 puncta. Scale bar, 10 µm. E, Within the NAc, a greater density of TH puncta colocalized with VGLUT2 in the NAc shell compared with the NAc core (Kruskal–Wallis H test, p = 0.031), but there was no significant effect of rotenone (p = 0.061). Data are mean ± SEM. N = 3-6 per group. *p < 0.05 compared with vehicle. ##p < 0.05 compared with CPu. See Extended Data Figure 6-1.

Tables

  • Figures
  • Extended Data
    • View popup
    Table 1.

    Primary antibody information

    AntigenAntibody catalog informationCompanyHost speciesImmunohistochemistry/immunocytochemistry concentration
    THAB1542EMD MilliporeSheep1:2000
    VGLUT2Ab79157AbcamMouse1:500
    VGLUT2135403Synaptic SystemsRabbit1:250
    β-ActinAb8226AbcamMouse1:1000

Extended Data

  • Figures
  • Tables
  • Figure 6-1

    TH and VGLUT2 pixel overlap in the NAc is greater than overlap that occurs by randomly distributed fluorescent pixels (supporting Fig. 6). Measurement of Pearson's correlation coefficient (Pearson's r) of TH and VGLUT2 pixels in the NAc is greater than correlation of TH and VGLUT2 after the pixels have been randomized in the images. N = 9 per group. **p < 0.01 (Wilcoxon matched pairs signed-rank test). Download Figure 6-1, TIF file.

Back to top

In this issue

The Journal of Neuroscience: 41 (22)
Journal of Neuroscience
Vol. 41, Issue 22
2 Jun 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Ed Board (PDF)
Email

Thank you for sharing this Journal of Neuroscience article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
VGLUT2 Is a Determinant of Dopamine Neuron Resilience in a Rotenone Model of Dopamine Neurodegeneration
(Your Name) has forwarded a page to you from Journal of Neuroscience
(Your Name) thought you would be interested in this article in Journal of Neuroscience.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
VGLUT2 Is a Determinant of Dopamine Neuron Resilience in a Rotenone Model of Dopamine Neurodegeneration
Silas A. Buck, Briana R. De Miranda, Ryan W. Logan, Kenneth N. Fish, J. Timothy Greenamyre, Zachary Freyberg
Journal of Neuroscience 2 June 2021, 41 (22) 4937-4947; DOI: 10.1523/JNEUROSCI.2770-20.2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Request Permissions
Share
VGLUT2 Is a Determinant of Dopamine Neuron Resilience in a Rotenone Model of Dopamine Neurodegeneration
Silas A. Buck, Briana R. De Miranda, Ryan W. Logan, Kenneth N. Fish, J. Timothy Greenamyre, Zachary Freyberg
Journal of Neuroscience 2 June 2021, 41 (22) 4937-4947; DOI: 10.1523/JNEUROSCI.2770-20.2021
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • dopamine
  • glutamate
  • neurodegeneration
  • rotenone
  • tyrosine hydroxylase
  • VGLUT2

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Research Articles

  • The amyloid precursor protein modulates the position and length of the axon initial segment
  • Cortical Parvalbumin-Positive Interneuron Development and Function Are Altered in the APC Conditional Knockout Mouse Model of Infantile and Epileptic Spasms Syndrome
  • Post-synaptic NMDA Receptor Expression Is Required for Visual Corticocollicular Projection Refinement in the Mouse Superior Colliculus
Show more Research Articles

Neurobiology of Disease

  • The amyloid precursor protein modulates the position and length of the axon initial segment
  • Cortical Parvalbumin-Positive Interneuron Development and Function Are Altered in the APC Conditional Knockout Mouse Model of Infantile and Epileptic Spasms Syndrome
  • Early TNF-Dependent Regulation of Excitatory and Inhibitory Synapses on Striatal Direct Pathway Medium Spiny Neurons in the YAC128 Mouse Model of Huntington's Disease
Show more Neurobiology of Disease
  • Home
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Issue Archive
  • Collections

Information

  • For Authors
  • For Advertisers
  • For the Media
  • For Subscribers

About

  • About the Journal
  • Editorial Board
  • Privacy Policy
  • Contact
(JNeurosci logo)
(SfN logo)

Copyright © 2023 by the Society for Neuroscience.
JNeurosci Online ISSN: 1529-2401

The ideas and opinions expressed in JNeurosci do not necessarily reflect those of SfN or the JNeurosci Editorial Board. Publication of an advertisement or other product mention in JNeurosci should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in JNeurosci.